ABSTRACT Pharmacological intervention is a primary therapeutic strategy for Osteoarthritis (OA), however, improving the bioavailability of therapeutic agents remains a significant challenge. In this study, we developed oxygen‐propelled, glutathione (GSH)‐responsive stomatocyte nanomotors (MTX/MnO 2 ‐GSH‐stomatocytes) for osteoarthritis (OA) treatment. First, polymersomes were assembled composed of block copolymers containing a GSH‐cleavable disulfide linker, which were loaded with the therapeuti